Standard Biotools Inc Cash Flow Conversion Efficiency
Standard Biotools Inc cash flow conversion efficiency. Based on the latest financial reports, Standard Biotools Inc (LAB) has a cash flow conversion efficiency ratio of -0.019x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.31 Million) by net assets ($539.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Standard Biotools Inc (2006–2025)
Cash flow conversion efficiency of Standard Biotools Inc from 2006 to 2025. This chart illustrates how Standard Biotools Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Standard Biotools Inc share price for real-time trading data and today's change.
Standard Biotools Inc Cash Flow Conversion Ratio Explained
Standard Biotools Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Standard Biotools Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Standard Biotools Inc ranked by their cash flow conversion efficiency. Also see Standard Biotools Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ICBC Turkey Bank AS
IS:ICBCT
|
1.650x |
|
Stille AB
ST:STIL
|
0.015x |
|
Hiron-Trade Investments & Industrial Buildings Ltd
TA:HRON
|
0.015x |
|
Invercap
SN:INVERCAP
|
0.051x |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
N/A |
|
Anhui Hyea Aromas Co Ltd
SHE:300886
|
-0.011x |
|
Global Partner Acquisition II Corp
NASDAQ:GPAC
|
0.297x |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
0.136x |
Annual Cash Flow Conversion Efficiency for Standard Biotools Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Standard Biotools Inc from 2006 to 2025. Review LAB FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $424.29 Million | $-74.35 Million | -0.175x | +42.38% |
| 2024-12-31 | $471.72 Million | $-143.45 Million | -0.304x | -204.01% |
| 2023-12-31 | $-148.05 Million | $-43.29 Million | 0.292x | -73.35% |
| 2022-12-31 | $-81.47 Million | $-89.37 Million | 1.097x | +335.52% |
| 2021-12-31 | $94.60 Million | $-44.06 Million | -0.466x | -320.10% |
| 2020-12-31 | $139.05 Million | $-15.42 Million | -0.111x | +51.63% |
| 2019-12-31 | $153.61 Million | $-35.21 Million | -0.229x | +34.41% |
| 2018-12-31 | $72.12 Million | $-25.20 Million | -0.349x | +55.14% |
| 2017-12-31 | $30.93 Million | $-24.10 Million | -0.779x | -6.06% |
| 2016-12-31 | $53.23 Million | $-39.10 Million | -0.734x | -143.23% |
| 2015-12-31 | $114.90 Million | $-34.70 Million | -0.302x | -100.77% |
| 2014-12-31 | $150.42 Million | $-22.62 Million | -0.150x | -818.07% |
| 2013-12-31 | $97.12 Million | $-1.59 Million | -0.016x | +90.57% |
| 2012-12-31 | $100.66 Million | $-17.48 Million | -0.174x | +43.68% |
| 2011-12-31 | $56.90 Million | $-17.54 Million | -0.308x | -606.80% |
| 2010-12-31 | $-189.17 Million | $-11.51 Million | 0.061x | -45.87% |
| 2009-12-31 | $-173.62 Million | $-19.51 Million | 0.112x | -38.04% |
| 2008-12-31 | $-158.34 Million | $-28.72 Million | 0.181x | +8.64% |
| 2007-12-31 | $-130.33 Million | $-21.76 Million | 0.167x | -20.53% |
| 2006-12-31 | $-106.17 Million | $-22.31 Million | 0.210x | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more